TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12634583

Group type: EXPERIMENTAL
Intervention: Individualized homeopathic medicine
Number of subjects: 242

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 242
Study: 10073156

Group type: EXPERIMENTAL
Intervention: Faecal occult blood tests (FOBT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flexible sigmoidoscopy, colonoscopy, double-contrast barium enema
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pilot colorectal cancer screening programmes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Faecal occult blood testing outside a population screening programme
Number of subjects: 0
Study: 10163712

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 1695783

Group type: EXPERIMENTAL
Intervention: Nonsurgical or surgical treatment for BPH
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systematic assessment of symptomatology and baseline minimal urodynamic evaluation
Number of subjects: 0
Study: 324177

Group type: EXPERIMENTAL
Intervention: Live dysentery Sonne vaccine (3 to 25 milliard live microbial cells, single and triple immunization schemes)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Live dysentery Sonne vaccine
Number of subjects: 0
Study: 31438413

Group type: EXPERIMENTAL
Intervention: Connected system for telerehabilitation
Number of subjects: 15
Study: 28712987

Group type: EXPERIMENTAL
Intervention: TAILORED intervention (intensive nurse-directed discussion of end-of-life decision control preferences)
Number of subjects: 166

Group type: COMPARATOR
Intervention: CONTROL intervention (discussion of nutrition)
Number of subjects: 166
Study: 25557395

Group type: EXPERIMENTAL
Intervention: Emotion Regulation Group Therapy (ERGT)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Ongoing outpatient therapy
Number of subjects: 61
Study: 24781217

Group type: EXPERIMENTAL
Intervention: Nocturnal non-invasive positive pressure ventilation (NIV)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 201
Study: 21924382

Group type: EXPERIMENTAL
Intervention: Nonlinear mixed model (conditional)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Marginal proportional hazards model with robust standard errors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clustered logrank test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clustered permutation test (non-parametric)
Number of subjects: 0
Study: 19211596

Group type: EXPERIMENTAL
Intervention: Exploratory factor analysis (EFA) on motor and non-motor symptoms in PD
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Confirmatory factor analysis based on EFA findings
Number of subjects: 397

Group type: EXPERIMENTAL
Intervention: Multiple regression analyses on resulting factors
Number of subjects: 397
Study: 17972451

Group type: EXPERIMENTAL
Intervention: Fresh whole blood (FWB) prime
Number of subjects: 100

Group type: COMPARATOR
Intervention: Packed red blood cell (PRBC) prime
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: < 5 kg FWB prime
Number of subjects: 100

Group type: COMPARATOR
Intervention: < 5 kg PRBC prime
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Fresh whole blood (FWB)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Pre-bypass ultrafiltration (PBUF)
Number of subjects: 100
Study: 15151729

Group type: EXPERIMENTAL
Intervention: Office hystroscopy (Group II)
Number of subjects: 421
Study: 12378744

Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pamidronic acid
Number of subjects: 0
Study: 9824184

Group type: EXPERIMENTAL
Intervention: Ketorolac (60 mg loading dose followed by 30 mg every 6 hours for a maximum of 24 hours)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Magnesium sulfate (initial 6 g intravenous bolus followed by continuous infusion therapy 2 to 6 g/hr)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 88
Study: 7926139

Group type: EXPERIMENTAL
Intervention: 1 mg/kg injected locally in the ectopic gestational sac and 1 mg/kg by IM administration 48 hours later
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1 mg/kg locally
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 0.5 mg/kg locally
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 1 mg/kg by IM administration
Number of subjects: 48
Study: 3617193

Group type: EXPERIMENTAL
Intervention: Combined supplement of iron, thiamine, riboflavin, and vitamin C for 3 months
Number of subjects: 190

Group type: COMPARATOR
Intervention: Placebo for 3 months
Number of subjects: 190
Study: 28842994

Group type: EXPERIMENTAL
Intervention: Preservative- and adjuvant-free trivalent split vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 27871520

Group type: EXPERIMENTAL
Intervention: Cisatracurium
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Rocuronium
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Neostigmine 0.05 mg kg‐1
Number of subjects: 120
Study: 25192259

Group type: EXPERIMENTAL
Intervention: 2.5mg letrozole
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 5mg letrozole
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: 7.5mg letrozole
Number of subjects: 88

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 88
Study: 22638811

Group type: EXPERIMENTAL
Intervention: d-amphetamine 10 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: d-amphetamine 40 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: d-amphetamine (both doses)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Number of subjects: 18
Study: 20919666

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Carotid artery endarterectomy (CEA)
Number of subjects: 4
Study: 18665373

Group type: EXPERIMENTAL
Intervention: Bisacodyl
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 19954476

Group type: EXPERIMENTAL
Intervention: Direct hemoperfusion with polymyxin B-immobilized fiber (DHP-PMX)
Number of subjects: 12
Study: 15820077

Group type: EXPERIMENTAL
Intervention: Lymphatic chemotherapy (LC) - subcutaneously injected with 4 ml of carboplatin-activated carbon suspension (20 mg of carboplatin) around the primary tumor.
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intravenous chemotherapy (VC) - intravenously injected with an equal dose of aqueous carboplatin.
Number of subjects: 60
Study: 11422760

Group type: EXPERIMENTAL
Intervention: Lead chelation therapy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 30
Study: 9205819

Group type: EXPERIMENTAL
Intervention: MP suleptanate (250 mg intramuscular injection)
Number of subjects: 20

Group type: COMPARATOR
Intervention: MP succinate (250 mg intramuscular injection)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: MP suleptanate
Number of subjects: 20

Group type: COMPARATOR
Intervention: MP succinate
Number of subjects: 20
Study: 7954994

Group type: EXPERIMENTAL
Intervention: Midazolam loading dose of 0.03 mg.kg-1 and infusion rate of 0.5 micrograms.kg-1.min-1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Midazolam loading dose of 0.06 mg.kg-1 and infusion rate of 1.0 micrograms.kg-1.min-1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Midazolam loading dose of 0.1 mg.kg-1 and infusion rate of 1.5 micrograms.kg-1.min-1
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Morphine given in increments of 2.0 mg iv prn for analgesia
Number of subjects: 30

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 30
Study: 3475886

Group type: EXPERIMENTAL
Intervention: Gastric bypass (GBY)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Gastroplasty (GPL)
Number of subjects: 57
Study: 31308209

Group type: EXPERIMENTAL
Intervention: Giant cell arteritis (GCA) patients
Number of subjects: 767

Group type: COMPARATOR
Intervention: Matched population controls
Number of subjects: 767
Study: 30838110

Group type: EXPERIMENTAL
Intervention: 10G drain
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: 12G drain
Number of subjects: 105

Group type: COMPARATOR
Intervention: No drain
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 105
Study: 28606095

Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg once weekly
Number of subjects: 0
Study: 26724628

Group type: EXPERIMENTAL
Intervention: Combined EVD and Ommaya reservoir with urokinase (20,000 IU/dose)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Combined EVD and Ommaya reservoir
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional EVD alone
Number of subjects: 60
Study: 24335723

Group type: EXPERIMENTAL
Intervention: Absorbable gelatin sponge (Gelfoam)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no absorbable gelatin sponge)
Number of subjects: 82
Study: 22344063

Group type: EXPERIMENTAL
Intervention: Diet and aerobic training
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Diet and resistance training
Number of subjects: 73

Group type: COMPARATOR
Intervention: Diet only
Number of subjects: 73
Study: 19294387

Group type: EXPERIMENTAL
Intervention: CI-1033 50 mg daily (arm A)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: CI-1033 150 mg daily (arm B)
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: CI-1033 450 mg/day x 14 days every 21 days (arm C)
Number of subjects: 194
Study: 17709456

Group type: EXPERIMENTAL
Intervention: Multiple-micronutrient-fortified beverage
Number of subjects: 1125

Group type: COMPARATOR
Intervention: Nonfortified beverage (Control)
Number of subjects: 1125
Study: 15563362

Group type: EXPERIMENTAL
Intervention: 200 mg ketoconazole administered orally every 24 h for 29 days
Number of subjects: 0
Study: 12035596

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% administered in monotherapy (2 times a day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1% administered in adjunctive therapy (3 times a day)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Brinzolamide in combination with other therapies
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Brinzolamide 1%
Number of subjects: 26
Study: 9560041

Group type: EXPERIMENTAL
Intervention: Prematil‐LCP
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Prematil
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Human milk
Number of subjects: 20
Study: 7813597

Group type: EXPERIMENTAL
Intervention: Immune intervention protocols avoiding immunosuppressants
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Supporting the defence of islet cells against inflammatory attack
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reducing exposure to putative diabetogenic dietary factors during infancy
Number of subjects: 0
Study: 3310629

Group type: EXPERIMENTAL
Intervention: Sucralfate (1 g three times a day one‐half hour before meals for four weeks)
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo (1 g three times a day one‐half hour before meals for four weeks)
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study: 29497286

Group type: EXPERIMENTAL
Intervention: Flat insoles
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Textured insoles
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control group (no insoles)
Number of subjects: 100
Study: 27639557

Group type: EXPERIMENTAL
Intervention: Guided Act and Feel Indonesia (GAF-ID) - Internet-based behavioral activation treatment with support from lay counselors.
Number of subjects: 312

Group type: COMPARATOR
Intervention: Psychoeducation (PE) - online-delivered minimal psychoeducation without any support.
Number of subjects: 312
Study: 25016780

Group type: EXPERIMENTAL
Intervention: CRP serum concentrations in patients with adenomas located proximally (8.674 +/- 9.19 microg/ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: TNF-alpha concentration in patients with adenomas (24.51 +/- 13.50 pg/ml)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IL-6 serum level in patients with colon adenomas (19.80 +/- 7.44 pg/ml)
Number of subjects: 60
Study: 23786283

Group type: EXPERIMENTAL
Intervention: Current exposure to dampness
Number of subjects: 46051

Group type: EXPERIMENTAL
Intervention: Damp homes
Number of subjects: 46051
Study: 20002646

Group type: EXPERIMENTAL
Intervention: Methyl aminolevulinate (MAL)‐PDT
Number of subjects: 14
Study: 18824995

Group type: COMPARATOR
Intervention: NAA measurement using H-MR spectroscopy at 3 days post-injury
Number of subjects: 13

Group type: COMPARATOR
Intervention: NAA measurement using H-MR spectroscopy at 15 days post-injury
Number of subjects: 13

Group type: COMPARATOR
Intervention: NAA measurement using H-MR spectroscopy at 30 days post-injury
Number of subjects: 13

Group type: COMPARATOR
Intervention: NAA measurement using H-MR spectroscopy at 45 days post-injury (for those with second concussive injury)
Number of subjects: 13

Group type: COMPARATOR
Intervention: NAA measurement using H-MR spectroscopy at 15 days post-second injury
Number of subjects: 13
Study: 17119800

Group type: EXPERIMENTAL
Intervention: Wrist immobilization (neutral-position wrist splint) for two weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: No wrist immobilization
Number of subjects: 52
Study: 12037755

Group type: EXPERIMENTAL
Intervention: Nonsurgical management (group 1)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Surgical management (group 2)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Overall morbidity
Number of subjects: 82
Study: 11188564

Group type: EXPERIMENTAL
Intervention: Intradermal lidocaine
Number of subjects: 50

Group type: COMPARATOR
Intervention: No local anesthetic
Number of subjects: 50
Study: 7559897

Group type: EXPERIMENTAL
Intervention: GnRH analog (Buserelin) in combination with cyproterone acetate (Androcur); n = 23
Number of subjects: 40

Group type: COMPARATOR
Intervention: Long acting GnRH analog (Decapeptyl Depot); n = 17
Number of subjects: 40
Study: 1967134

Group type: EXPERIMENTAL
Intervention: Patients who wished to die at home (34 patients, 58%)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Patients who died in hospital (32 patients)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Patients with more favorable circumstances (41 patients, 67%)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Patients who preferred to die in hospital (10 patients, 16%)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Patients who preferred to die in hospice (9 patients, 15%)
Number of subjects: 98
Study: 7378234

Group type: EXPERIMENTAL
Intervention: Practolol 0.4 mg kg‐1 and atropine 1.5 mg i.v. shortly before anaesthesia; practolol 0.2 mg kg‐1 during anaesthesia
Number of subjects: 25

Group type: COMPARATOR
Intervention: Atropine 0.5 mg before anaesthesia
Number of subjects: 25
Study: 31705591

Group type: EXPERIMENTAL
Intervention: Psycho-educational intervention programme (n = 102)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Attention from intervener (n = 100)
Number of subjects: 202
Study: 31679508

Group type: EXPERIMENTAL
Intervention: Video Animated Activity Questionnaire (AAQ)
Number of subjects: 200

Group type: COMPARATOR
Intervention: HOOS/KOOS paper questionnaire
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Correlation between AAQ and HOOS/KOOS
Number of subjects: 200
Study: 27671861

Group type: EXPERIMENTAL
Intervention: Preoperative embolization (POE) with polyvinyl alcohol (PVA) particles
Number of subjects: 64

Group type: COMPARATOR
Intervention: Surgery without POE
Number of subjects: 64
Study: 26403361

Group type: EXPERIMENTAL
Intervention: Passive ankle dorsiflexion stretching for 15 min per leg, four days per week for six weeks.
Number of subjects: 13

Group type: COMPARATOR
Intervention: Normal routine (control group).
Number of subjects: 13
Study: 23673793

Group type: EXPERIMENTAL
Intervention: Keep It Up! intervention
Number of subjects: 102

Group type: COMPARATOR
Intervention: Online didactic HIV knowledge condition
Number of subjects: 102
Study: 21345132

Group type: EXPERIMENTAL
Intervention: Problem-solving skills training based on metacognitive principles
Number of subjects: 32

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 32
Study: 19330391

Group type: COMPARATOR
Intervention: Titanium-coated cups
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Hydroxyapatite-coated cups
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study: 17353513

Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg) + HCTZ (25 mg)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Irbesartan (150 mg) + HCTZ (25 mg)
Number of subjects: 489

Group type: EXPERIMENTAL
Intervention: Amlodipine (5 mg) + HCTZ (25 mg)
Number of subjects: 489

Group type: COMPARATOR
Intervention: Placebo + HCTZ (25 mg)
Number of subjects: 489
Study: 14729863

Group type: EXPERIMENTAL
Intervention: -1131C allele carriers (n = 54)
Number of subjects: 608

Group type: EXPERIMENTAL
Intervention: 19W carriers (n = 44)
Number of subjects: 608

Group type: COMPARATOR
Intervention: Gemfibrozil treatment
Number of subjects: 608
Study: 11502525

Group type: EXPERIMENTAL
Intervention: Clinafloxacin (CI‐960) administered intravenously and orally, dosage not specified, single and twice-daily doses.
Number of subjects: 0
Study: 9474074

Group type: EXPERIMENTAL
Intervention: Palliative chemotherapy
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: PROSQOLI
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: QLQ‐C30
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: PROSQOLI linear analog scale
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: PROSQOLI and QLQ‐C30
Number of subjects: 161
Study: 8582390

Group type: EXPERIMENTAL
Intervention: Beta-blocker (acebutalol or atenolol)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 19
Study: 2198911

Group type: EXPERIMENTAL
Intervention: Dilevalol (n = 9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Atenolol (n = 9)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dilevalol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Dilevalol and Atenolol
Number of subjects: 18
Study: 219509

Group type: EXPERIMENTAL
Intervention: timolol-hydrochlorothiazide-amiloride combination
Number of subjects: 283

Group type: COMPARATOR
Intervention: beta-blocker (timolol) alone
Number of subjects: 283

Group type: COMPARATOR
Intervention: combination of two diuretics (hydrochlorothiazide + amiloride)
Number of subjects: 283

Group type: EXPERIMENTAL
Intervention: beta-blocker/diuretic combination
Number of subjects: 283
Study: 29901581

Group type: EXPERIMENTAL
Intervention: Suprapatellar approach
Number of subjects: 0

Group type: COMPARATOR
Intervention: Infrapatellar approach
Number of subjects: 0
Study: 26541570

Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 4736

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4736
Study: 24568963

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin
Number of subjects: 6500

Group type: EXPERIMENTAL
Intervention: Low-dose clonidine
Number of subjects: 6500

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6500

Group type: EXPERIMENTAL
Intervention: Single measurement of serum creatinine between 3 and 12 months after surgery
Number of subjects: 6500
Study: 22950716

Group type: EXPERIMENTAL
Intervention: Intensified physical activity counseling (5 sessions integrated into routine maternity visits, monthly group meetings)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Usual care (conventional practices continued)
Number of subjects: 399
Study: 20230447

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal tablet (FBT)
Number of subjects: 252

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study: 18849226

Group type: EXPERIMENTAL
Intervention: Right ventricular outflow tract (RVOT) pacing
Number of subjects: 32

Group type: COMPARATOR
Intervention: Right ventricular apex (RVA) pacing
Number of subjects: 32
Study: 15888205

Group type: EXPERIMENTAL
Intervention: AR immunostaining in prostate cancer epithelial nuclei
Number of subjects: 40

Group type: COMPARATOR
Intervention: AR immunostaining in benign prostate
Number of subjects: 40

Group type: COMPARATOR
Intervention: Percentage of immunopositive nuclei and percentage of immunopositive nuclear area
Number of subjects: 40
Study: 12960909

Group type: COMPARATOR
Intervention: Enoxaparin (30 mg subcutaneously every 12 hr)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Dalteparin (5000 IU subcutaneously once daily)
Number of subjects: 95
Study: 10672813

Group type: EXPERIMENTAL
Intervention: Mepitel silicone net dressings
Number of subjects: 45

Group type: COMPARATOR
Intervention: Paraffin gauze dressings
Number of subjects: 45
Study: 8554022

Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 24

Group type: COMPARATOR
Intervention: Tissue plasminogen activator (TPA)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Streptokinase and TPA
Number of subjects: 24
Study: 2061445

Group type: EXPERIMENTAL
Intervention: Topical 10% cyclosporine in oily solution
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: PUVA
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intravenous thymopentin
Number of subjects: 26
Study: 6352005

Group type: EXPERIMENTAL
Intervention: prednimustine continuously; 40 mg/m2 d
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: prednimustine intermittently; 160 mg/m2 d 1 to 5, repeated every three weeks
Number of subjects: 201

Group type: COMPARATOR
Intervention: chlorambucil 8 mg/m2 d plus prednisolone 8 mg/m2 d, both given continuously
Number of subjects: 201
Study: 4085127

Group type: EXPERIMENTAL
Intervention: Internal kinesthetic imagery training
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Internal visual imagery training
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: External visual imagery training
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control training group
Number of subjects: 59
Study: 30851006

Group type: EXPERIMENTAL
Intervention: Self-managed titration of Gla-300
Number of subjects: 0

Group type: COMPARATOR
Intervention: Physician-managed titration of Gla-300
Number of subjects: 0
Study: 29417371

Group type: EXPERIMENTAL
Intervention: Repeated health checks (maximum of three checks between 1982 and 1994)
Number of subjects: 17845

Group type: COMPARATOR
Intervention: Control group (no health checks)
Number of subjects: 17845
Study: 26601770

Group type: EXPERIMENTAL
Intervention: Autonomic regulation therapy (ART) with chronic vagus nerve stimulation
Number of subjects: 25